 WALTHAM, MA ACCESSWIRE September 23, 2019 EyeGate Pharmaceuticals, Inc. EYEG EyeGate or the Company, a clinical-stage company focused on developing products for treating disorders of the eye, announced today that the Company has regained compliance with Nasdaq Listing Rule 5550 a2, which concerns minimum bid price listing requirements. We are pleased to be in full compliance with this listing standard and that the matter has been deemed closed by Nasdaq, said Stephen From, EyeGates Chief Executive Officer. EyeGates lead product, Ocular Bandage Gel OBG, is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface. 